Clinical trials: Spasticity With Multiple Sclerosis
Multiple Sclerosis, Spasticity
Dry Needling in Multiple Sclerosis
The investigators are doing this study to see if a treatment called dry needling improves muscle spasticity (muscle tightness) in people who have Multiple Sclerosis.
- Trial name
- NCT06394310
- Testing
- Dry needling
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Kansas Medical Center
Multiple Sclerosis
Smart Monitoring Assessing Spasticity-related Health
This observational study seeks to investigate the underlying of spasticity in patients with multiple sclerosis (MS) by employing multimodal monitoring techniques.
- Trial name
- SMASH (NCT06937723)
- Testing
- Device: Smartwatch (Withings Scanwatch)
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Spasticity, Spasticity in Participants With Multiple Sclerosis
Nerve Root Block in Spasticity
In this work the investigators propose to briefly apply kilohertz frequency alternating current via PNS device placed next to the isolated nerve in 4 patients undergoing peripheral neurectomy, just before cutting the nerve.
- Conditions
- Spasticity, Spasticity in Participants With Multiple Sclerosis, Spasticity Post Stroke, Spasticity Related to Any Cause Except Cerebral Palsy
- Trial name
- NCT06868342
- Testing
- High-frequency nerve conduction block
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- Walton Centre NHS Foundation Trust
Spinal Cord Injuries, Periodic Limb Movement Disorder
Periodic Leg Movements' Diagnosis in Spinal Cord Injury: Actigraphy as an Alternative for Polysomnography?
Periodic Limb Movements during Sleep (PLMs) are episodes of repetitive, stereotypical, hallux or foot movements. They could induce sleep disturbance, fatigue, daytime sleepiness and impaired quality of life but also increased…
- Trial name
- ACTI-MPJ-BM (NCT04618978)
- Testing
- PSG and actigraphy recording
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Spasticity With Multiple Sclerosis
Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
This study will be conducted to evaluate the effect of multiple doses of nabiximols compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Lower Limb Muscle Tone-6 [LLMT-6]) in…
- Trial name
- RELEASE MSS5 (NCT04984278)
- Testing
- Nabiximols
- Where
- 30 sites in United States, Czechia and 3 more
- Volunteers
- 56 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis (MS)
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
This trial is being conducted to demonstrate the efficacy of nabiximols, compared with placebo, when added to standard of care, in the treatment of muscle spasms associated with multiple sclerosis (MS).
- Trial name
- RELEASE MSS3 (NCT04203498)
- Testing
- Nabiximols
- Where
- 37 sites in United States, Czechia and 3 more
- Volunteers
- 139 people
- Sponsor
- Jazz Pharmaceuticals
Sclerosis, Multiple, MS (Multiple Sclerosis)
EXOPULSE Mollii Suit, Motor Function & Multiple Sclerosis (EXOSEP 2)
The goal of this clinical trial is to demonstrate the improvement of motor functions related symptoms in patients with MS and spasticity using Exopulse Mollii suit stimulation in Multiple Sclerosis patients with spasticity.
- Conditions
- Sclerosis, Multiple, MS (Multiple Sclerosis), Spasticity, Muscle, Spastic
- Trial name
- NCT05857280
- Testing
- EXOPULSE Mollii Suit Stimulation
- Where
- United Arab Emirates
- Volunteers
- 36 people
- Sponsor
- Sheikh Shakhbout Medical City
Multiple Sclerosis, Spasticity
miR-142-3p as Potential Biomarker of Synaptopathy in MS
Inflammatory synaptopathy is a prominent pathogenic mechanism in multiple sclerosis (MS) and in its mouse model, which can cause excitotoxic damage by long-lasting excessive synaptic excitation and, consequentially, drives…
- Trial name
- NCT03999788
- Testing
- lumbar puncture and blood withdrawal, Intermittent theta burst stimulation (iTBS) therapeutic protocol for spasticity
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Neuromed IRCCS
Sclerosis, Multiple, MS (Multiple Sclerosis)
EXOPULSE Mollii Suit, Spasticity, Muscular Oxygenation & Multiple Sclerosis (ENNOX 2)
The goal of this clinical trial is to demonstrate the improvement of muscular oxygenation in patients with Multiple Sclerosis and spasticity using Exopulse Molli suit stimulation.
- Conditions
- Sclerosis, Multiple, MS (Multiple Sclerosis), Spastic, Spasticity, Muscle
- Trial name
- NCT05912595
- Testing
- EXOPULSE Mollii Suit Stimulation
- Where
- United Arab Emirates
- Volunteers
- 36 people
- Sponsor
- Sheikh Shakhbout Medical City
Multiple Sclerosis
Non-invasive Spinal Cord Stimulation for Spasticity Control and Augmentation of Voluntary Motor Control in Individuals With Multiple Sclerosis
Epidural spinal cord stimulation (SCS) is currently regarded as one of the most promising intervention methods to improve motor function in individuals with severe spinal cord injury.
- Trial name
- noSpasMS (NCT04486209)
- Testing
- transcutaneous spinal cord stimulation
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Medical University of Vienna
Spasticity in Participants With Multiple Sclerosis
Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
This study will be conducted to evaluate the effect of multiple doses of nabiximols as adjunctive therapy compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Modified Ashworth Scale…
- Trial name
- RELEASE MSS1 (NCT04657666)
- Testing
- Nabiximols
- Where
- 16 sites in Czechia, Poland
- Volunteers
- 68 people
- Sponsor
- Jazz Pharmaceuticals
Spasticity, Multiple Sclerosis
A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)
The purpose of this study is to determine whether Sativex® versus Placebo is effective in the relief of symptoms of spasticity in subjects with multiple sclerosis, who have been identified as having a capacity to respond to…
- Trial name
- NCT00681538
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 572 people
- Sponsor
- Jazz Pharmaceuticals
Spasticity, Multiple Sclerosis
Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis
The purpose of this study is to evaluate the maintenance of effect after long-term treatment with Sativex® in subjects with symptoms of spasticity due to Multiple Sclerosis (MS) who have been receiving long-term benefit from…
- Trial name
- NCT00702468
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Jazz Pharmaceuticals
Spasticity, Multiple Sclerosis
A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.
The purpose of this study is to evaluate the efficacy, safety and tolerability of Sativex® in subjects diagnosed with MS and spasticity.
- Trial name
- NCT00711646
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 189 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Spasticity
A Study of the Long-term Safety of Sativex Use
Subjects who had previously received GW-1000-02 in a GW study who opted to continue using it in the long-term were monitored for ongoing tolerability and evidence of clinical benefit.
- Conditions
- Multiple Sclerosis, Spasticity, Pain
- Trial name
- NCT01606137
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 507 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Spasticity
A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients
A study to compare the change in cognitive performance and psychological status of patients with spasticity due to Multiple Sclerosis when treated with Sativex or placebo, added to existing anti-spasticity therapy over a period…
- Trial name
- NCT01964547
- Testing
- Sativex
- Where
- Czechia
- Volunteers
- 121 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Spasticity
A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.
- Trial name
- NCT01610687
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 137 people
- Sponsor
- Jazz Pharmaceuticals
Spinal Cord Injuries, Multiple Sclerosis
Validity and Reliability of Turkish Version Leg Activity Measure
Patient-filled scales minimize the burden of data collection for clinicians in a clinical setting. Therefore, Leg activity measure, a new self-report measure of active and passive function in the leg, has been developed.
- Conditions
- Spinal Cord Injuries, Multiple Sclerosis, Stroke
- Trial name
- NCT05182411
- Testing
- assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Kahramanmaras Sutcu Imam University
Multiple Sclerosis, Spasticity, Muscle
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
Spasticity is a common complication in MS and occurs in up to 84% of patients. The main sign of spasticity is resistance to passive limb movement characterized by increased resistance to stretching, clonus, and exaggerated deep…
- Trial name
- OS440-3005 (NCT03319732)
- Testing
- Arbaclofen
- Where
- United States
- Volunteers
- 323 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Multiple Sclerosis, Spasticity, Muscle
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disease of the central nervous system (CNS) that is regarded as the foremost cause of non-traumatic neurologic disability in adults in North America.
- Trial name
- OS440-3004 (NCT03290131)
- Testing
- Arbaclofen
- Where
- 30 sites in Belarus, Bosnia and Herzegovina and 5 more
- Volunteers
- 536 people
- Sponsor
- RVL Pharmaceuticals, Inc.